Neurotrope Inc.
Developing a new approach to combating Alzheimer's disease and other neurodegenerative diseases.
Developing a new approach to combating Alzheimer's disease and other neurodegenerative diseases.
Neurotrope Inc. is a United States based clinical-stage biotech company founded in 2012. The company's slogan "Developing a new approach to combating Alzheimer's disease and other neurodegenerative diseases" embodies their mission to discover restorative therapeutics for patients with life-altering neurodegenerative diseases and development disorders. Neurotrope is leveraging Bryostatin-1 and its analogues to develop targeted therapeutics for neurodegenerative diseases and developmental disorders. Their last investment was a $21.90M Series A investment in 02 September 2013. The company's pipeline includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer’s Disease, Fragile X Syndrome and Niemann-Pick Type C. With a strong focus on Biotechnology and Health Care industries, Neurotrope Inc. is at the forefront of pioneering novel drug therapies.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $21.90M | - | 02 Sep 2013 | |
| Seed Round | Unknown | 1 |
|
01 Jan 2013 |
No recent news or press coverage available for Neurotrope Inc..
We care about your data, and we'd love to use cookies make your experience better.
